GO:1903780 negative regulation of cardiac conduction: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903780 (negative regulation of cardiac conduction) describes any biological process that reduces the frequency, rate, or extent of cardiac conduction.
• Cardiac conduction is normally modulated by the autonomic nervous system, where sympathetic and parasympathetic inputs interact to fine-tune heart rate and conduction velocity.
• Pharmacological agents such as calcium-channel blockers can slow cardiac conduction, providing a clinical example of negative regulation.
• MicroRNAs and epigenetic regulators, including miR-193a-3p, miR-27a-3p, and DNMT3A/miR-145 feedback loops, have been implicated in modulating cardiac conduction and related myocardial processes.
• Dysregulation of negative regulation of cardiac conduction contributes to arrhythmias, heart failure, and other cardiovascular diseases.
• CRISPR-based knockout, knock-in, and overexpression models are powerful tools to dissect the causal role of specific genes in negative regulation of cardiac conduction.
Description
Cardiac conduction is the process by which electrical impulses propagate through the heart to coordinate contraction. Negative regulation of cardiac conduction (GO:1903780) refers to any process that stops, prevents, or reduces the frequency, rate, or extent of this electrical signaling. This regulation is essential for maintaining normal heart rhythm and adapting cardiac output to physiological demands. The autonomic nervous system, particularly the interplay between sympathetic and parasympathetic branches, provides a classic example of negative regulation, where vagal stimulation slows heart rate and conduction velocity. Pharmacological interventions, such as calcium-channel blocking agents, also exemplify negative regulation by reducing conduction through the atrioventricular node. Understanding the molecular and cellular mechanisms underlying GO:1903780 is critical for developing therapies for arrhythmias and heart failure. Recent studies have identified microRNAs and epigenetic modifiers that contribute to this regulation. For instance, miR-193a-3p and ALKBH5 are involved in autophagy modulation in myocardial ischemia/reperfusion, which can affect cardiac conduction. Similarly, miR-27a-3p derived from pericardial adipose tissue extracellular vesicles activates AMPKα2-mediated mitophagy and improves heart failure, indirectly influencing conduction. The DNMT3A/miR-145 feedback loop regulates autophagy in cardiac fibroblasts and myocardial fibrosis, which can alter conduction properties. These findings highlight the complexity of negative regulation of cardiac conduction and the need for robust experimental models to study it.
negative regulation of cardiac conduction At A Glance
| GO ID | GO:1903780 |
|---|---|
| GO term | negative regulation of cardiac conduction |
| Ontology | biological_process |
| Synonym | down regulation of cardiac conduction, down-regulation of cardiac conduction, downregulation of cardiac conduction, inhibition of cardiac conduction |
| Major function | Reduces the frequency, rate, or extent of cardiac conduction |
| Related processes | Autonomic regulation of heart rate, calcium channel signaling, microRNA-mediated regulation |
| Key regulators | Sympathetic and parasympathetic nervous systems, calcium channels, microRNAs (e.g., miR-193a-3p, miR-27a-3p), DNMT3A/miR-145 |
| Disease relevance | Arrhythmias, heart failure, myocardial ischemia/reperfusion injury |
What Is GO:1903780?
GO:1903780, negative regulation of cardiac conduction, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of cardiac conduction. This includes molecular events that decrease the speed or reliability of electrical impulse propagation in the heart, such as ion channel modulation, autonomic signaling, and pharmacological effects.
Why Is negative regulation of cardiac conduction Important in Cell Biology?
Negative regulation of cardiac conduction is vital for normal cardiac physiology, allowing the heart to adjust its rate and rhythm in response to stress, rest, and metabolic demands. Dysregulation of this process can lead to arrhythmias, heart block, and heart failure, making it a key area of cardiovascular research.
• Maintains normal heart rhythm by preventing excessive conduction that could lead to tachyarrhythmias.
• Enables fine-tuning of heart rate via autonomic nervous system inputs.
• Provides a target for pharmacological interventions such as calcium-channel blockers.
• Involved in the pathophysiology of heart failure and myocardial ischemia/reperfusion injury.
• Regulated by microRNAs and epigenetic factors, offering novel therapeutic targets.
• Critical for understanding congenital and acquired conduction disorders.
• Impacts cardiac output and overall cardiovascular health.
• Serves as a model for studying gene-environment interactions in cardiac electrophysiology.
• Relevant to drug development for arrhythmias and heart rate control.
• Highlights the importance of balanced autonomic tone for cardiac function.
What Happens During negative regulation of cardiac conduction?
Autonomic modulation of cardiac conduction
In simple terms: The nervous system can slow down the heart's electrical signals.
The autonomic nervous system plays a central role in negative regulation of cardiac conduction. Sympathetic and parasympathetic branches interact to modulate heart rate and conduction velocity. Parasympathetic (vagal) stimulation releases acetylcholine, which slows conduction through the sinoatrial and atrioventricular nodes, while sympathetic stimulation increases conduction. The balance between these inputs determines the net effect on cardiac conduction.
Calcium channel blockade
In simple terms: Certain drugs can block calcium channels to slow electrical conduction in the heart.
Calcium-channel blocking agents, such as verapamil and diltiazem, reduce calcium influx in cardiac pacemaker and conduction tissues, thereby slowing conduction. This pharmacological negative regulation is used clinically to treat arrhythmias and hypertension.
MicroRNA-mediated regulation
In simple terms: Small RNA molecules can fine-tune gene expression to affect heart conduction.
MicroRNAs such as miR-193a-3p and miR-27a-3p have been shown to modulate autophagy and mitophagy in cardiac cells, indirectly influencing cardiac conduction and heart function. For example, miR-193a-3p targets ALKBH5 to regulate autophagy in myocardial ischemia/reperfusion, while miR-27a-3p from pericardial adipose tissue extracellular vesicles activates AMPKα2-mediated mitophagy and improves heart failure.
Epigenetic regulation by DNMT3A/miR-145
In simple terms: Epigenetic changes can alter gene activity and affect heart conduction.
The DNA methyltransferase DNMT3A and miR-145 form a bidirectional negative feedback loop that regulates autophagy in cardiac fibroblasts, impacting myocardial fibrosis. Fibrosis can disrupt normal conduction pathways, contributing to arrhythmias.
Key Genes Involved in GO:1903780 negative regulation of cardiac conduction
The following genes and non-coding RNAs have been implicated in negative regulation of cardiac conduction or related cardiac processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| miR-193a-3p | Regulates autophagy via ALKBH5 | Implicated in myocardial ischemia/reperfusion injury |
| ALKBH5 | RNA demethylase, target of miR-193a-3p | Modulates autophagy in cardiac cells |
| miR-27a-3p | Regulates AMPKα2-mediated mitophagy | Improves heart failure via pericardial adipose tissue EVs |
| AMPKα2 | Energy sensor, promotes mitophagy | Mediates protective effects in heart failure |
| DNMT3A | DNA methyltransferase | Regulates autophagy in cardiac fibroblasts |
| miR-145 | Regulates DNMT3A expression | Forms feedback loop affecting myocardial fibrosis |
| CACNA1C | Voltage-gated calcium channel | Target of calcium-channel blockers, affects conduction |
| CACNA1D | Voltage-gated calcium channel | Contributes to pacemaker activity |
| SCN5A | Sodium channel | Mutations cause Brugada syndrome and conduction defects |
| KCNQ1 | Potassium channel | Mutations cause long QT syndrome |
| HCN4 | Pacemaker channel | Regulates heart rate |
| ADRB1 | Beta-1 adrenergic receptor | Mediates sympathetic effects on conduction |
| CHRM2 | Muscarinic acetylcholine receptor | Mediates parasympathetic effects |
| GJA1 | Connexin 43 | Gap junction protein, affects conduction velocity |
| GJA5 | Connexin 40 | Gap junction protein in atria |
| NOS1 | Neuronal nitric oxide synthase | Modulates autonomic control of conduction |
| PITX2 | Transcription factor | Associated with atrial fibrillation |
How Is negative regulation of cardiac conduction Regulated?
Negative regulation of cardiac conduction is itself regulated by multiple mechanisms. The autonomic nervous system provides rapid, reversible control through sympathetic and parasympathetic inputs. Calcium-channel blockers can pharmacologically inhibit conduction. At the molecular level, microRNAs such as miR-193a-3p and miR-27a-3p modulate autophagy and mitophagy, which can influence cardiac conduction. Epigenetic regulators like DNMT3A and miR-145 form feedback loops that affect fibrosis and conduction.
negative regulation of cardiac conduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| miR-193a-3p | Myocardial ischemia/reperfusion injury | Knockout and overexpression in cardiomyocytes |
| miR-27a-3p | Heart failure | Knock-in and knockout in mouse models |
| DNMT3A | Myocardial fibrosis | Cardiac fibroblast-specific knockout |
| miR-145 | Myocardial fibrosis | Overexpression and knockout in cardiac fibroblasts |
| CACNA1C | Arrhythmias | Point mutation knock-in in mice |
Arrhythmias and conduction disorders
Dysregulation of negative regulation of cardiac conduction can lead to arrhythmias, including bradycardia, heart block, and tachyarrhythmias. For example, excessive parasympathetic tone can cause bradycardia, while loss of negative regulation may contribute to atrial fibrillation.
Heart failure
Heart failure is often associated with altered cardiac conduction and fibrosis. MicroRNAs such as miR-27a-3p and miR-193a-3p have been shown to modulate mitophagy and autophagy, influencing heart failure progression. The DNMT3A/miR-145 axis regulates fibrosis, which can disrupt conduction.
Myocardial ischemia/reperfusion injury
Ischemia/reperfusion injury can disrupt cardiac conduction. miR-193a-3p and ALKBH5 are involved in autophagy regulation during ischemia/reperfusion, suggesting a role in conduction abnormalities.
From negative regulation of cardiac conduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate cardiac conduction? | Knockout mouse or cardiomyocyte-specific KO |
| Does a specific mutation in gene X affect conduction? | Point mutation knock-in mouse |
| Does overexpression of gene X alter conduction? | Transgenic overexpression mouse |
| Does gene X interact with protein Y? | Tagged knock-in for co-IP |
| Does microRNA X regulate conduction? | miR knockout or overexpression mouse |
| Does epigenetic factor X affect conduction? | Conditional knockout in cardiac cells |
How to Study the negative regulation of cardiac conduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ECG | Heart rate, PR interval, QRS duration | In vivo conduction assessment |
| Patch clamp | Ion channel currents | Cellular electrophysiology |
| qPCR | Gene/miRNA expression | Validation of regulators |
| Western blot | Protein levels | Signaling pathway analysis |
| RNA-seq | Transcriptome changes | Discovery of novel regulators |
| Histology | Fibrosis, tissue structure | Conduction tissue remodeling |
| Immunofluorescence | Protein localization | Gap junction distribution |
| CRISPR screen | Gene function | High-throughput discovery |
Electrocardiography (ECG) and electrophysiology
ECG and intracardiac electrophysiology studies are used to measure conduction parameters such as PR interval, QRS duration, and heart rate in animal models and humans. These methods directly assess negative regulation of cardiac conduction.
Molecular biology techniques
Quantitative PCR, Western blotting, and RNA sequencing are used to measure expression of genes and microRNAs implicated in conduction regulation, such as miR-193a-3p, miR-27a-3p, and DNMT3A.
Histology and imaging
Histological staining and immunofluorescence can assess fibrosis and gap junction protein distribution, which affect conduction. Confocal imaging of connexins provides insights into conduction properties.
CRISPR screening and bioinformatics
Genome-wide CRISPR screens combined with bioinformatics can identify novel regulators of cardiac conduction. Pathway enrichment and network analysis help prioritize candidate genes.
How CRISPR Can Be Used to Study GO:1903780 negative regulation of cardiac conduction
Knockout
CRISPR knockout of candidate genes such as miR-193a-3p or DNMT3A in cardiac cell lines or animal models can reveal their role in negative regulation of cardiac conduction. For example, knockout of miR-193a-3p may alter autophagy and conduction properties.
Point Mutation
Introducing point mutations in ion channel genes like CACNA1C can mimic human conduction disorders and help study the effects on cardiac conduction.
Knock-in
Knock-in of tagged proteins or reporter genes allows tracking of protein localization and interactions in cardiac tissues, facilitating the study of conduction regulators.
Overexpression
Overexpression of microRNAs such as miR-27a-3p or genes like AMPKα2 can be achieved via CRISPR activation or transgenic models to assess their impact on cardiac conduction and heart function.
How EDITGENE Supports negative regulation of cardiac conduction Research
Researchers studying negative regulation of cardiac conduction-related genes often need to determine whether a candidate gene is causally involved in modulating electrical signaling in the heart. This requires precise genetic models that can knockout, mutate, knock-in, or overexpress specific genes in cardiac cells or whole organisms.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cardiac conduction research.
Frequently Asked Questions About negative regulation of cardiac conduction
What is negative regulation of cardiac conduction?
It is any process that reduces the frequency, rate, or extent of cardiac conduction, as defined by GO:1903780.
What genes are involved in negative regulation of cardiac conduction?
Genes include miR-193a-3p, miR-27a-3p, DNMT3A, miR-145, and ion channel genes like CACNA1C.
How does the autonomic nervous system negatively regulate cardiac conduction?
Parasympathetic stimulation releases acetylcholine, which slows conduction, while sympathetic stimulation increases it; the balance determines net effect.
What drugs negatively regulate cardiac conduction?
Calcium-channel blockers such as verapamil and diltiazem slow conduction by inhibiting calcium influx.
What diseases are associated with abnormal negative regulation of cardiac conduction?
Arrhythmias, heart failure, and myocardial ischemia/reperfusion injury.
How can CRISPR be used to study negative regulation of cardiac conduction?
CRISPR knockout, knock-in, point mutation, and overexpression models can dissect gene function in cardiac conduction.
What are the key methods to measure cardiac conduction?
ECG, patch clamp, and electrophysiology studies are standard methods.
What is the role of microRNAs in cardiac conduction?
MicroRNAs such as miR-193a-3p and miR-27a-3p modulate autophagy and mitophagy, influencing conduction.
How does fibrosis affect cardiac conduction?
Fibrosis disrupts gap junctions and electrical coupling, slowing conduction; DNMT3A/miR-145 regulate fibrosis.
What model organisms are used to study negative regulation of cardiac conduction?
Mice, rats, and human induced pluripotent stem cell-derived cardiomyocytes are commonly used.
Conclusion
Negative regulation of cardiac conduction (GO:1903780) is a critical biological process that fine-tunes electrical signaling in the heart. Dysregulation contributes to arrhythmias, heart failure, and other cardiovascular diseases. Recent research has uncovered roles for microRNAs, epigenetic regulators, and ion channels in this process. CRISPR-based models and advanced bioinformatics are essential for dissecting the underlying mechanisms and identifying therapeutic targets.
References
- 1. Wang D et al.. 2024. Suxiao Jiuxin Pill alleviates myocardial ischemia/reperfusion-induced autophagy via miR-193a-3p/ALKBH5 pathway.. Phytomedicine 125:155359 PMID: 38301300
- 4. Chen Z et al.. 2024. Huangqi-Danshen decoction improves heart failure by regulating pericardial adipose tissue derived extracellular vesicular miR-27a-3p to activate AMPKα2 mediated mitophagy.. Phytomedicine 135:156187 PMID: 39488874
- 5. Leonard RG et al.. 1982. Calcium-channel blocking agents.. Clin Pharm 1(1):17-33 PMID: 6764159
- 6. Levy MN. 1984. Cardiac sympathetic-parasympathetic interactions.. Fed Proc 43(11):2598-602 PMID: 6745448
- 7. Xu S et al.. 2023. Bidirectional negative feedback actions of DNMT3A and miR-145 in regulating autophagy in cardiac fibroblasts and affecting myocardial fibrosis.. J Bioenerg Biomembr 55(5):341-352 PMID: 37610521
